| Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. | |
| | |
MedLine Citation:
|
PMID: 19864114 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: This study evaluated the effectiveness of first- and second-generation antipsychotics in reducing family burden associated with schizophrenia. METHODS: The family caregivers of 623 SCID-diagnosed patients enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) randomly assigned to a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetiapine, risperidone or ziprasidone) were interviewed about resources provided and stresses experienced at baseline and followed for 18 months. Patient symptoms, side effects and service use were assessed as well. Hierarchical regression analyses evaluated the effect of treatment assignment on four burden factors: problem behavior, resource demands and disruption, impairment in activities of daily living and patient helpfulness. Intention-to-treat analyses with all available observations classified based on initial treatment assignment, including observations after medications changed were followed by secondary analyses excluding observations after the first medication change, i.e. only considering initial medication. RESULTS: Despite significant reductions on the problem behavior and resource demands/disruption factors, there were no significant differences between perphenazine and any of the second-generation medications. When only initial treatment period observations were included, patients were perceived as more helpful when medicated with perphenazine as compared to risperidone. In comparisons between second-generation drugs, patients on quetiapine were perceived as more helpful than those on risperidone (p=0.004). CONCLUSION: In this 18-month randomized trial, there was no evidence of superiority of second-generation antipsychotics in relieving family burden. |
| | |
Authors:
|
Deborah A Perlick; Robert A Rosenheck; Richard Kaczynski; Marvin S Swartz; Jose M Canive; Jeffrey A Lieberman |
Related Documents
:
|
11913674 - Management of weight gain in patients with schizophrenia. 2896084 - Altered balance in the autonomic nervous system in schizophrenic patients. 16696824 - Treatment adherence with antipsychotic medications in bipolar disorder. 8885584 - Medication treatment strategies in the mta study: relevance to clinicians and researchers. 20026694 - A practical approach to teaching medical ethics. 19005314 - Medical decision making: paternalism versus patient-centered (autonomous) care. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-10-28 |
Journal Detail:
|
Title: Schizophrenia research Volume: 116 ISSN: 1573-2509 ISO Abbreviation: Schizophr. Res. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-03 Completed Date: 2010-04-13 Revised Date: 2010-09-02 |
Medline Journal Info:
|
Nlm Unique ID: 8804207 Medline TA: Schizophr Res Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 118-25 Citation Subset: IM |
Copyright Information:
|
2009. Published by Elsevier B.V. |
Affiliation:
|
Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, New York 10029-6574, USA. debbieperlick@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antipsychotic Agents / economics*, therapeutic use* Attitude to Health Caregivers / psychology Cost-Benefit Analysis Double-Blind Method Family* / psychology Female Humans Longitudinal Studies Male Middle Aged Psychiatric Status Rating Scales Quality of Life Regression Analysis Schizophrenia / drug therapy*, economics* Schizophrenic Psychology Severity of Illness Index Statistics, Nonparametric Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
N01 MH90001/MH/NIMH NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents |
| Comments/Corrections | |
Comment In:
|
Evid Based Ment Health. 2010 Aug;13(3):84
[PMID:
20682824
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizoph...
Next Document: Suicide attempt in first-episode psychosis: A 7.4year follow-up study.